Please assess the completion status of the following clinical trial:

Trial Title: Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 35-55 Kg/m2~* Fasting Blood glucose \>140mg/dl~* Planned bariatric surgery~* Diabetic Medication (Metformin, Sulfonylurea, Insuline)~Exclusion Criteria:~* Known hypersensitivity against Liraglutid~* Pretreatment DPP-4 Inhibitors or GLP-1 Analogue the last 3 months~* HbA1c \>10%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- GLP-1 (Liraglutide) (Type: ACTIVE_COMPARATOR): Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).